vs
Side-by-side financial comparison of Celldex Therapeutics, Inc. (CLDX) and Anbio Biotechnology (NNNN). Click either name above to swap in a different company.
Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops targeted immunotherapies for hard-to-treat cancers and rare immunological diseases. Its pipeline covers antibody-drug conjugates, monoclonal antibodies and other novel therapies, serving patients with high unmet medical needs mainly across North America and Europe.
Anbio Biotechnology is a specialized in vitro diagnostic (IVD) biotechnology enterprise that develops, manufactures and markets a wide range of rapid testing solutions. Its product portfolio covers infectious disease detection, cardiovascular marker tests, food safety screening kits and supporting diagnostic tools, serving clinical labs, healthcare facilities and supervision bodies across global markets.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $120.0K | — | ||
| Q3 25 | $0 | — | ||
| Q2 25 | $730.0K | — | ||
| Q1 25 | $695.0K | — | ||
| Q4 24 | $1.2M | — | ||
| Q3 24 | $3.2M | — | ||
| Q2 24 | $2.5M | — | ||
| Q1 24 | $156.0K | — |
| Q4 25 | $-81.3M | — | ||
| Q3 25 | $-67.0M | — | ||
| Q2 25 | $-56.6M | — | ||
| Q1 25 | $-53.8M | — | ||
| Q4 24 | $-47.1M | — | ||
| Q3 24 | $-42.1M | — | ||
| Q2 24 | $-35.8M | — | ||
| Q1 24 | $-32.8M | — |
| Q4 25 | -72628.3% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -8747.5% | — | ||
| Q1 25 | -9027.2% | — | ||
| Q4 24 | -4768.3% | — | ||
| Q3 24 | -1633.5% | — | ||
| Q2 24 | -1854.2% | — | ||
| Q1 24 | -26030.8% | — |
| Q4 25 | -67764.2% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -7753.4% | — | ||
| Q1 25 | -7740.4% | — | ||
| Q4 24 | -4007.8% | — | ||
| Q3 24 | -1320.0% | — | ||
| Q2 24 | -1434.8% | — | ||
| Q1 24 | -21030.8% | — |
| Q4 25 | $-1.23 | — | ||
| Q3 25 | $-1.01 | — | ||
| Q2 25 | $-0.85 | — | ||
| Q1 25 | $-0.81 | — | ||
| Q4 24 | $-0.71 | — | ||
| Q3 24 | $-0.64 | — | ||
| Q2 24 | $-0.54 | — | ||
| Q1 24 | $-0.56 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
